| Literature DB >> 26535492 |
Ingrid E M Bank1,2, Leo Timmers2,3,4, Crystel M Gijsberts1,2, Ya-Nan Zhang5,6, Arend Mosterd7, Jiong-Wei Wang5,6, Mark Y Chan4, Vince De Hoog1,2, Sai Kiang Lim8, Siu Kwan Sze9, Carolyn S P Lam10, Dominique P V De Kleijn1,2,5,6.
Abstract
Cardiovascular disease (CVD) is the leading cause of death worldwide and its prevalence is expected to rise rapidly worldwide in the coming decades. Atherosclerosis, the syndrome underlying CVD, is a chronic progressive disease of the arteries already present at a young age. Strokes, heart attacks and heart failure are acute CVD events that occur after decades, however, and require timely diagnosis and treatment. Plasma extracellular vesicles (EVs) are microstructures with a lipid bilayer membrane involved in hemostasis, inflammation and injury. Both EV-counts and EV-content are associated with CVD and the identification of plasma EVs is a novel source of blood-based biomarkers with the potential to improve diagnosis and prognosis of CVD. Presented in this review is an overview of the current use of EVs in CVD and a discussion of the need for robust and easy isolation technologies for plasma EV subsets. This is needed to bring this promising field towards clinical application in the patient.Entities:
Keywords: Plasma extracellular vesicles; biomarker; cardiovascular disease; flow cytometry; microparticles; vesicle content; vesicle counts
Mesh：
Substances：
Year: 2015 PMID： 26535492 DOI： 10.1586/14737159.2015.1109450
Source DB: PubMed Journal: Expert Rev Mol Diagn ISSN： 1473-7159 Impact factor: 5.225